Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Diroximel fumarate
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 19, 2021
Lead Product(s) : Diroximel fumarate
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Diroximel fumarate
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 19, 2021
Lead Product(s) : Diroximel fumarate
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Diroximel fumarate
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : VUMERITY (diroximel fumarate) is approved next-generation oral fumarate for treatment of adults with relapsing-remitting multiple sclerosis. Data from Phase 3 EVOLVE-MS-2 study demonstrated low discontinuation rates due to its gastrointestinal tolerabili...
Product Name : Vumerity
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 17, 2021
Lead Product(s) : Diroximel fumarate
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Diroximel fumarate
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Single and Multiple Ascending Dose Study of JW1601 for Healthy Volunteers
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 12, 2019
Lead Product(s) : Diroximel fumarate
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Diroximel fumarate
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Alkermes Plc
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 28, 2017
Lead Product(s) : Diroximel fumarate
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Alkermes Plc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Diroximel fumarate
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Alkermes Plc
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 18, 2015
Lead Product(s) : Diroximel fumarate
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Alkermes Plc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Diroximel fumarate
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of ALKS 8700, a Monomethyl Fumarate (MMF) Molecule, in Healthy Adults
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 28, 2014
Lead Product(s) : Diroximel fumarate
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable